Landiolol

Description

Landiolol ONO1101 is a highly selective, ultra-short-acting competitive inhibitor of ?1 adrenergic receptors. Landiolol specifically blocks cardiac ?1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-?-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels such as L-type calcium current and inward rectifier potassium current and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury.